Eisai retreats from Biogen deal on Aduhelm

Japanese drugmaker Eisai (TYO: 4523) has backed out of its 50:50 profit sharing deal with US biotech company Biogen (Nasdaq: BIIB) on the Alzheimer’s drug Aduhelm (aducanumab).

Effective as of January 1, 2023, Eisai will receive tiered royalties based on net sales of Aduhelm rather than sharing global profits and losses. The royalty rate starts at 2% and reaches 8% when, or if, annual sales exceed $1 billion.

"The goal of maximizing the value of both Aduhelm and lecanemab"As from now, Biogen’s existing final decision-making rights on Aduhelm have converted to sole decision making and commercialization rights worldwide.